The KEYNOTE-756 trial is a crucial study investigating the use of pembrolizumab, an anti-PD-1 antibody, in combination with neoadjuvant endocrine therapy for patients with high-risk, HR-positive, HER2-negative early breast cancer. This evidence concerns the gene ERBB2 and breast cancer.